Federated Hermes Inc. Raises Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Federated Hermes Inc. boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 4,708.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,474 shares of the company’s stock after buying an additional 43,549 shares during the quarter. Federated Hermes Inc.’s holdings in Y-mAbs Therapeutics were worth $303,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics during the 3rd quarter worth about $100,000. Strs Ohio grew its holdings in shares of Y-mAbs Therapeutics by 20.1% during the third quarter. Strs Ohio now owns 89,000 shares of the company’s stock worth $485,000 after buying an additional 14,900 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Y-mAbs Therapeutics by 20.1% in the third quarter. Victory Capital Management Inc. now owns 109,500 shares of the company’s stock valued at $597,000 after buying an additional 18,320 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in Y-mAbs Therapeutics by 12.2% in the 3rd quarter. Los Angeles Capital Management LLC now owns 303,920 shares of the company’s stock valued at $1,656,000 after acquiring an additional 32,994 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Y-mAbs Therapeutics by 258.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock valued at $448,000 after purchasing an additional 59,201 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 0.6 %

Shares of Y-mAbs Therapeutics stock opened at $17.15 on Friday. Y-mAbs Therapeutics, Inc. has a twelve month low of $4.60 and a twelve month high of $20.90. The stock has a market capitalization of $752.42 million, a price-to-earnings ratio of -35.00 and a beta of 0.78. The business’s 50 day simple moving average is $15.71 and its 200-day simple moving average is $10.92.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. The business had revenue of $23.36 million during the quarter, compared to analyst estimates of $21.72 million. Sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the transaction, the senior vice president now directly owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 21.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

YMAB has been the topic of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target (up previously from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. HC Wainwright lifted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Canaccord Genuity Group increased their price target on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. Finally, BMO Capital Markets increased their target price on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $16.57.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.